First Presentation of Systemic Lupus Erythematosus in a 24-Year-Old Male following mRNA COVID-19 Vaccine
Corresponding Author
Yael Raviv
Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorBatya Betesh-Abay
Recanati School for Community Health Professions, Department of Nursing, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel and Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorYuliya Valdman-Grinshpoun
Department of Dermatology, Soroka University Medical Center, Beer Sheva, Israel bgu.ac.il
Search for more papers by this authorLiora Boehm-Cohen
Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorMichael Kassirer
Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorIftach Sagy
Rheumatology Unit and Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorCorresponding Author
Yael Raviv
Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorBatya Betesh-Abay
Recanati School for Community Health Professions, Department of Nursing, Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel and Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorYuliya Valdman-Grinshpoun
Department of Dermatology, Soroka University Medical Center, Beer Sheva, Israel bgu.ac.il
Search for more papers by this authorLiora Boehm-Cohen
Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorMichael Kassirer
Pulmonary Institute, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorIftach Sagy
Rheumatology Unit and Clinical Research Center, Soroka University Medical Center, Beer-Sheva, Israel bgu.ac.il
Search for more papers by this authorAbstract
The SARS-CoV-2 viral pandemic has had an immeasurable global impact, resulting in over 5 million deaths worldwide. Numerous vaccines were developed in an attempt to quell viral dissemination and reduce symptom severity among those infected. Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of antinuclear autoantibodies (ANAs) with heterogenic clinical manifestations, secondary to immune complex deposition in a multitude of organ systems. There are scarcely reported cases of SLE development following COVID-19 mRNA vaccination. We present a case of a 24-year-old male without preexisting conditions or family history of autoimmune disorders, presenting with SLE following the first dose of the SARS-CoV-2 Pfizer-BioNTech mRNA vaccine.
Conflicts of Interest
The authors declare no conflicts of interest.
Open Research
Data Availability
Data were ethically extracted from the patient's file.
References
- 1 Dörner T. and Furie R., Novel paradigms in systemic lupus erythematosus, Lancet. (2019) 393, 2344–2358, https://doi.org/10.1016/S0140-6736(19)30546-X, 2-s2.0-85066735264.
- 2 Pons-Estel G. J., Alarcón Graciela G. S., Scofield L., Reinlib L., and Cooper G. S., Understanding the epidemiology and progression of systemic lupus erythematosus, Seminars in Arthritis and Rheumatism. (2010) 39, no. 4, 257–268, https://doi.org/10.1016/j.semarthrit.2008.10.007, 2-s2.0-74449091545.
- 3 Yang J., Yang X., Zou H., Chu Y., and Li M., Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus, Rheumatology. (2011) 50, no. 8, 1366–1372, https://doi.org/10.1093/rheumatology/ker116, 2-s2.0-84862833461.
- 4 Miyara M., Amoura Z., Parizot C., Badoual C., Dorgham K., Trad S., Nochy D., Debré P., Piette J.-C., and Gorochov G., Global natural regulatory T cell depletion in active systemic lupus erythematosus, The Journal of Immunology. (2005) 175, no. 12, 8392–8400, https://doi.org/10.4049/jimmunol.175.12.8392, 2-s2.0-29144516273.
- 5 WHO Coronavirus (COVID-19) Dashboard, https://covid19.who.int/.
- 6 Polack F. P., Thomas S. J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J. L., Pérez Marc G., Moreira E. D., Zerbini C., Bailey R., Swanson K. A., Roychoudhury S., Koury K., Li P., Kalina W. V., Cooper D., Frenck R. W., Hammitt L. L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D. B., Mather S., Dormitzer P. R., Şahin U., Jansen K. U., and Gruber W. C., Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine, New England Journal of Medicine. (2020) 383, no. 27, 2603–2615, https://doi.org/10.1056/nejmoa2034577.
- 7 Rosen B., Waitzberg R., and Israeli A., Israel’s rapid rollout of vaccinations for COVID-19, Israel Journal of Health Policy Research. (2021) 10, no. 1, 6, https://doi.org/10.1186/s13584-021-00440-6.
- 8 Mathieu E., Ritchie H., Ortiz-Ospina E., Roser M., Hasell J., Appel C., Giattino C., and Rodés-Guirao L., A global database of COVID-19 vaccinations, Nature Human Behaviour. (2021) 5, no. 7, 947–953, https://doi.org/10.1038/s41562-021-01122-8.
- 9 Barda N., Dagan N., and Ben-Shlomo Y., Safety of the BNT162b2 mRNA COVID-19 vaccine in a nationwide setting, New England Journal of Medicine. (2021) 385, 1078–1090, https://doi.org/10.1056/nejmoa2110475.
- 10 Vojdani A. and Kharrazian D., Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases, Clinical Immunology. (2020) 217, 108480, https://doi.org/10.1016/j.clim.2020.108480.
- 11 Ehrenfeld M., Tincani A., Andreoli L., Cattalini M., Greenbaum A., Kanduc D., Alijotas-Reig J., Zinserling V., Semenova N., Amital H., and Shoenfeld Y., Covid-19 and autoimmunity, Autoimmunity Reviews. (2020) 19, no. 8, 102597, https://doi.org/10.1016/j.autrev.2020.102597.
- 12 Liu Y., Sawalha A. H., and Lu Q., COVID-19 and autoimmune diseases, Current Opinion in Rheumatology. (2021) 33, no. 2, 155–162, https://doi.org/10.1097/bor.0000000000000776.
- 13 Tang W., Askanase A. D., Khalili L., and Merrill J. T., SARS-CoV-2 vaccines in patients with SLE, Lupus Science & Medicine. (2021) 8, no. 1, e000479, https://doi.org/10.1136/lupus-2021-000479.
- 14 Mason A., Anver H., and Lwin M., Lupus, vaccinations and COVID-19: what we know now, Lupus. (2021) 30, no. 10, 1541–1552, https://doi.org/10.1177/09612033211024355.
- 15 Aringer M., Costenbader K., Daikh D., Brinks R., Mosca M., Ramsey-Goldman R., Smolen J. S., Wofsy D., Boumpas D. T., Kamen D. L., Jayne D., Cervera R., Costedoat-Chalumeau N., Diamond B., Gladman D. D., Hahn B., Hiepe F., Jacobsen S., Khanna D., Lerstrøm K., Massarotti E., McCune J., Ruiz-Irastorza G., Sanchez-Guerrero J., Schneider M., Urowitz M., Bertsias G., Hoyer B. F., Leuchten N., Tani C., Tedeschi S. K., Touma Z., Schmajuk G., Anic B., Assan F., Chan T. M., Clarke A. E., Crow M. K., Czirják L., Doria A., Graninger W., Halda-Kiss B., Hasni S., Izmirly P. M., Jung M., Kumánovics G., Mariette X., Padjen I., Pego-Reigosa J. M., Romero-Diaz J., Rúa-Figueroa Fernández Í., Seror R., Stummvoll G. H., Tanaka Y., Tektonidou M. G., Vasconcelos C., Vital E. M., Wallace D. J., Yavuz S., Meroni P. L., Fritzler M. J., Naden R., Dörner T., and Johnson S. R., 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus, Annals of the Rheumatic Diseases. (2019) 78, 1151–1159, https://doi.org/10.1136/annrheumdis-2018-214819, 2-s2.0-85070711882.
- 16 Sang A., Zheng Y.-Y., and Morel L., Contributions of B cells to lupus pathogenesis, Molecular Immunology. (2014) 62, no. 2, 329–338, https://doi.org/10.1016/j.molimm.2013.11.013, 2-s2.0-84908121724.
- 17 Zhao S., Wang Y., Liang Y., Zhao M., Long H., Ding S., Yin H., and Lu Q., MicroRNA-126 regulates DNA methylation in CD4+ T cells and contributes to systemic lupus erythematosus by targeting DNA methyltransferase 1, Arthritis & Rheumatism. (2011) 63, no. 5, 1376–1386, https://doi.org/10.1002/art.30196, 2-s2.0-79955569628.
- 18 Crowson A. N. and Magro C., The cutaneous pathology of lupus erythematosus: a review, Journal of Cutaneous Pathology. (2001) 28, no. 1, 1–23, https://doi.org/10.1034/j.1600-0560.2001.280101.x, 2-s2.0-0035178544.
- 19 Lee E., Cines D. B., and Gernsheimer T., Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination, American Journal of Hematology. (2021) 96, no. 5, 534–537.
- 20 Chamling B., Vehof V., and Drakos S., Occurrence of acute infarct-like myocarditis following COVID-19 vaccination: just an accidental co-incidence or rather vaccination-associated autoimmune myocarditis?, Clinical Research in Cardiology. (2021) 110, no. 11, 1850–1854.
- 21 Bril F., Al Diffalha S., and Dean M., Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?, Journal of Hepatology. (2021) 75, no. 1, 222–224.
